Beam Therapeutics Inc Dossier - Source-backed chat

Beam Therapeutics Inc

BEAMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.79

Intrinsic Value $43.08median of 2 methodsbased on filings through 30 Jun 2026

Market Price $24.45Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 76% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+76%)

Data confidence Sign in to view data confidence

Market Cap $2.5B

Enterprise Value $2.4B

Shares Outstanding 107.7M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Beam Therapeutics is a pioneer in precision genetic medicine, leveraging its proprietary base editing platform to make single-base changes without double-stranded DNA breaks. This technology offers a highly differentiated safety and efficacy profile compared to first-generation CRISPR-Cas9 systems. With a robust cash position of $1.2 billion extending its runway into mid-2029, Beam is well-capitalized to transition into a commercial-stage company. Key near-term catalysts include the anticipated BLA submission for risto-cel in sickle cell disease as early as year-end 2026 and the initiation of a pivotal cohort for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) in the second half of 2026 under an accelerated approval pathway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$26.00

Mean target$52.15

High · most bullish analyst$80.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$26.0015%

Regulatory delays push the risto-cel BLA submission past 2027, or safety concerns emerge during the BEAM-302 pivotal trial. Slow patient enrollment in the rare disease programs extends development timelines, increasing cash burn and forcing dilutive capital raises before commercial revenues materialize.

Base CaseCentral scenario

$52.1560%

Matches the consensus mean

Beam successfully submits the BLA for risto-cel by early 2027 and initiates the pivotal cohort for BEAM-302 in H2 2026. Clinical data for BEAM-301 in GSDIa and the initiation of the BEAM-304 trial in PKU progress as planned. The company maintains its disciplined spending, preserving its cash runway into 2029.

Bull CaseUpside scenario

$80.0025%

Risto-cel achieves rapid FDA approval and commercial uptake in sickle cell disease, establishing a strong revenue stream. Simultaneously, BEAM-302 successfully completes its pivotal cohort under the accelerated approval pathway, demonstrating robust and durable AAT biomarker restoration, leading to early commercialization in AATD. The platform's validation triggers additional high-value pharmaceutical collaborations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary base editing technology avoids double-stranded DNA breaks, minimizing off-target risks and offering a superior safety profile.
Strong balance sheet with $1.2 billion in cash, cash equivalents, and marketable securities, providing an operational runway into mid-2029.
Clear regulatory pathways, including alignment with the FDA on an accelerated approval pathway for BEAM-302 based on 12-month biomarker data.
Diversified pipeline spanning hematology (risto-cel), genetic liver diseases (BEAM-302, BEAM-301), and metabolic disorders (BEAM-304).

Key Investment Risks

Clinical and regulatory risks inherent in developing novel gene-editing modalities, including potential long-term safety concerns.
Commercial execution risks, particularly in competing against established therapies and other gene-editing players in sickle cell disease.
High operational cash burn typical of pre-commercial biotechnology companies, which could lead to future dilution if commercialization is delayed.

Thesis Invalidation Triggers

Failure to obtain FDA approval or significant delays in the BLA submission for risto-cel.
Emergence of serious adverse events or off-target editing toxicities in ongoing clinical trials for BEAM-302 or risto-cel.
Inability to initiate the pivotal cohort for BEAM-302 in the second half of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.